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analysed in a single assay run. Intra-assay precision for GH was 4% CV in the range 4-40 mUlL, and assay sensitivity was 0·1 to 0·02 ml.J/L. Fig. I shows the lowest GH levels achieved. In 22 of the 24 subjects GH levels suppressed with the nadir occurring at either 90 (n = 12)or 120min (n = 10). The two subjects who failed to suppress had basal levels of <0·5 mUlL and showed a paradoxical increase ofGH at each time-point, to 6·8 and 3·0 mUlL at ISO min. In the 24 subjects plasma glucose (mean±SD) was 5·2±0·7 mrnol/L at 0 min, 8·2 ± 1·8 mrnol/L at 30 min and 6·9 ± 1·7 mmol/L at 60 min. Maximal plasma glucose was achieved at 30 min in 17 subjects and at 60 min in the remaining 7. There was no relationship between the maximal plasma glucosẽ Estimation of plasma growth hormone (GH) during a 50 g oral glucose tolerance test (OGTT) is widely used in the investigation of suspected acromegaly and in monitoring its response to treatment. A plasma GH of < 2 mUlL measured in terms of International Reference Preparation (IRP) 66/217 by radioimmunoassay (RIA) is considered normal in the majority of UK laboratories, although data from the UK External Quality Assessment Scheme reveal that cut-offs as low as I mUj l.; and as high as 10mUIL, are used.
Two developments suggest a need for reappraisal of the normal GH response. Firstly, since 1982 the 50 g OGTT has been superseded by a 75 g OGTT in the diagnosis of diabetes mellitus, I and it would seem desirable to standardise the procedure for both conditions. Secondly, the introduction of sensitive immunoradiometric assays (IRMA) for GH has made it possible now to measure levels that are below the detection limit of most RIA This short study was performed, therefore, to define the normal plasma GH response measured by IRMA during a 75 g OGTT.
The normal subjects comprised 16 men and 8 women (mean age 28·6 years, range 21-48) who did not abuse alcohol and had no clinical evidence of pituitary, liver or renal disease. They were fasted overnight and rested in the sitting position for 45 min prior to insertion ofa Venflow catheter in the antecubital fossa at -30 min. Following two basal samples, at -IS and 0 min, 75 g of glucose in 200 mL water (freshly prepared) was given orally at 09.00 h. Blood was collected at 30 min intervals for ISO min into heparinised tubes on ice, and the plasma assayed for GH using the level and the nadir GH level. The two subjects who failed to show suppression of GH had normal glucose tolerance with no evidence of enhanced glucose absorption, nor were there other distinguishing features, e.g. stress, physical activity," that might have accounted for the lack of suppression.
Among the 22 subjects who suppressed, there was a continuous spectrum of GH levels at the nadir, varying from <0·1 mUjL (undetectable) to 1·0-1' 5 mU jL. Five of the 7 volunteers who did not suppress to < O'5 m U jL were women. There was a positive correlation between basal levels and the nadir GH level (r=0'46, n=24, P< 0,02, Spearman rank correlation test). These data are consistent with cessation of GH secretion following the glucose load, and clearance of circulating GH with a half-life of 25 min.' Mean body mass index (8MI) in the group was within the recommended range of 20-25 kgjm at 23·6 ± 0·6 kg/m? and there was no correlation between 8MI and the nadir GH level.
We conclude that GH, as measured by a sensitive and specific IRMA, remains detectable in the majority of normal subjects during a 75 g OGTT, and that an upper limit of normal of 2 m U jL remains appropriate. However, the finding in two of our volunteers ofa paradoxical increase in GH underlines the importance of considering basal and post-glucose levels in interpreting test results.
